Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer
PLOS One · 03.06.2026 · 21 (6) · e0349231
DOI: 10.1371/journal.pone.0349231 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 03.06.2026. Verfasst von Hayley Reddington und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Thoracic Surgery, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of Amer…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Lung Neoplasms, Pneumonectomy, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lobectomy remains the standard surgical approach for resectable non-small cell lung cancer (NSCLC), but sublobar resection is increasingly considered, particularly for small, early-stage tumors. The role of sublobar resection after neoadjuvant therapy is unclear. We compared survival after sublobar resection versus lobectomy among patients with T1N1-2M0 NSCLC treated with neoadjuvant therapy.
Methods
Using the National Cancer Database (2011–2021), we identified patients ≥18 years with clinical stage T1N1-2M0 NSCLC who received neoadjuvant chemotherapy, chemoradiation, or chemoimmunotherapy followed by resection within 8 months. Patients with pneumonectomy, metastases, positive margins were excluded. Patients were grouped by resection type: sublobar (wedge or segmentectomy) vs. lobectomy (including bilobectomy and extended). Survival was assessed via Kaplan–Meier analysis and multivariable Cox regression.
Results
Of 2,257 patients, 148 (6.6%) underwent sublobar resection. Compared to lobectomy, sublobar resection was associated with fewer lymph nodes examined (24% vs. 54% with >10 nodes, p < 0.001) and shorter hospital stays (3.9 vs. 5.3 days, p < 0.001). Stage distribution was similar. One-year survival was comparable for both groups in stage II and III disease. At 5 years, survival was lower for stage III patients undergoing sublobar resection (48.6% vs. 59.9%, p < 0.01), with adjusted analysis confirming worse survival (HR = 1.41, p = 0.013).
Conclusions
Among patients with T1N1-2M0 NSCLC treated with neoadjuvant therapy, sublobar resection was associated with similar short-term but inferior long-term survival compared to lobectomy. Lobectomy remains preferred for patients with adequate reserve, though sublobar resection may be appropriate for select patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Division of Thoracic Surgery, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
- University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
ORCID-Profile: Isabel Emmerick, Javier Diaz Collante, Feiran Lou
Zitieren
APA
Reddington, H., Emmerick, I., Diaz Collante, J., Maini, A., Kanzaria, R., Crawford, A., Phillips, W., Maxfield, M., Uy, K., & Lou, F. (2026). Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer. PLOS One, 21(6), e0349231. https://doi.org/10.1371/journal.pone.0349231
Vancouver
Reddington H, Emmerick I, Diaz Collante J, Maini A, Kanzaria R, Crawford A, et al. Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer. PLOS One. 2026;21(6):e0349231. doi:10.1371/journal.pone.0349231
BibTeX
@article{Reddington2026,
author = {Reddington, Hayley and Emmerick, Isabel and Diaz Collante, Javier and Maini, Aniket and Kanzaria, Raghav and Crawford, Allison and Phillips, William and Maxfield, Mark and Uy, Karl and Lou, Feiran},
title = {Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {6},
pages = {e0349231},
doi = {10.1371/journal.pone.0349231}
}
EUVIMED